Send to:

Choose Destination

ERX033401: Foxa1 and Foxa2 are essential for gender dimorphism in liver cancer
1 ILLUMINA (Illumina Genome Analyzer IIx) run: 36.7M spots, 1.3G bases, 785.9Mb downloads

Design: Foxa1 and Foxa2 are essential for gender dimorphism in liver cancer
Submitted by: University of Pennsylvania, Bushman Laboratory (UPENNBL)
Study: Foxa1 and Foxa2 are essential for gender dimorphism in liver cancer
Sample: E-MTAB-805:Untreated-Female
SAMEA1464827 • ERS074990 • All experiments • All runs
Organism: Mus musculus
Name: FA2
Instrument: Illumina Genome Analyzer IIx
Strategy: ChIP-Seq
Selection: ChIP
Layout: SINGLE
Construction protocol: Briefly, 14-15 day old mice were injected with DEN (20 mg/kg body weight) (Sigma) to initiate tumor growth. Beginning at 28 days, mice were injected with TCPOBOP (3 mg/kg bodyweight) (Sigma) once every two weeks for a total of eight times to promote tumor growth.DEN-induced liver injury experiments were carried out as described previously (Naugler etal., 2007), except that 50 mg/kg body weight Faslodex or estrogen were intraperitoneally injected daily for seven days before DEN treatment. The human samples were not treated. Chromatin was extracted from mouse livers following the protocol described in Li et al. NSMB 2011 [PMID 21623366]. ChIP was performed on the liver chromatin samples. ChIP-DNA was prepared for sequencing with the Illumina GAII sequencer at the Functional Genomics Center at the Institute for Diabetes, Obesity and Metabolismat the University of Pennsylvania.
Spot descriptor:

Experiment attributes: (show all 5 attributes...) (hide...)
Experimental Factor: ORGANISM: Mus musculus
Experimental Factor: SEX: female
Experimental Factor: TREATMENT: Untreated
Experimental Factor: GENOTYPE: Foxa1loxP/loxP;Foxa2loxP/loxP
Experimental Factor: IMMUNOPRECIPITATE: Foxa2
Runs: 1 run, 36.7M spots, 1.3G bases, 785.9Mb
Run# of Spots# of BasesSizePublished


Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center